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Abstract
Background: The close temporal association between onset of some connective tissue diseases and cancer
suggests a paraneoplastic association. Adult patients with scleroderma with anti-RNA polymerase III autoantibodies
and adult patients with dermatomyositis with anti-transcriptional intermediary factor 1 (anti-TIF1) or anti-nuclear
matrix protein 2 (anti-NXP2) autoantibodies have a significantly increased risk of developing cancer. Autoantibodies
may serve as biomarkers for early detection of cancer and also could be relevant for prediction of responses to
immune therapies. We aimed to test whether myositis and scleroderma specific or associated autoantibodies are
detectable in individuals with lung cancer.
Methods: Serum from 60 Caucasian patients with lung cancer (30 with small cell lung cancer, 30 with non-small
cell lung cancer) was screened for myositis and scleroderma specific and associated autoantibodies by radiolabelled
immunoprecipitation.
Results: Anti-TIF1, anti-NXP2 or anti-RNA polymerase III autoantibodies were not detected in any of the 60 patients
with lung cancer. Anti-glycyl-transfer RNA (tRNA) synthetase (anti-EJ) autoantibodies were detected in one patient
with non-small cell lung cancer. No other known myositis or scleroderma autoantibodies were identified.
Conclusions: Myositis and scleroderma specific autoantibodies, including anti-TIF1, anti-NXP2 and anti-RNA
polymerase III, are rare in patients with lung cancer without an autoimmune disease. We report here the first
case of anti-EJ autoantibodies being detected in a patient with lung cancer without clinical or radiographic
evidence of the anti-synthetase syndrome.
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Background
A close temporal association has been observed between
the onset of some autoimmune connective tissue diseases
(CTD) and various cancers, suggesting that the appearance
of a CTD may sometimes represent a paraneoplastic
phenomenon. For example, adult patients with dermato-
myositis (DM) with anti-transcription intermediary factor
1 (anti-TIF1) autoantibodies have a dramatically increased
risk of developing cancer compared to the general popula-
tion [1]. Presence of anti-nuclear matrix protein 2
(anti-NXP2) autoantibodies similarly is associated with an
increased cancer risk in adult DM [2]. A meta-analysis of
five studies [3] showed that the pooled standardized inci-
dence ratio for lung cancer among patients with DM is
19.74 (95% confidence interval 18.91–20.58), second only
to lymphatic and haematopoietic cancers.
DM comprises a subgroup of the idiopathic inflamma-
tory myopathies (IIM), a rare CTD spectrum character-
ized by inflammation of skeletal muscle (myositis) causing
weakness and associated disability. Extra-muscular mani-
festations occur in the lungs and skin, and temporally as-
sociated cancers are common. In addition to clinical
classification, IIM can be accurately classified according to
the presence of approximately 20 myositis-specific and
associated autoantibodies (MSA/MAA), identified in 60–
70% of adult patients with IIM. MSA are almost mutually
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exclusive, and predictive of an individual patient’s clin-
ical phenotype, including disease progression and treat-
ment response characteristics [4]. “Cancer associated
myositis” has been defined as myositis occurring in
association with an incident cancer diagnosed 3 years
either side of myositis onset, and a treatment-induced
cancer cure can be associated with a simultaneous
regression of the myositis. Recent evidence suggests
that scleroderma also represents a paraneoplastic
phenomenon, being similarly temporally associated
with cancers in some anti-RNA polymerase III-positive
patients [5]. The mechanism underlying this close tem-
poral association between cancer onset and certain
serologically defined subgroups of myositis and sclero-
derma is unknown.
In patients with cancer, a large number of autoanti-
bodies directed against intracellular tumour-associated
antigens have been identified. These autoantibodies may
be detected in patients’ serum prior to the initial presen-
tation of clinical cancer signs. Current theories suggest
that autoantibody production in patients with cancer
may result from changes in tissue protein expression,
altered protein structure, defects in tolerance and inflam-
mation and aberrant tissue degradation mechanisms [6]. In-
flammation in the tumour microenvironment may facilitate
the release of certain intracellular antigens to create reactive
neo-epitopes via aberrant protein expression and/or altered
protein structure through somatic mutation or conform-
ational change. These changes facilitate the generation of
autoantibodies against these altered proteins.
For paraneoplastic rheumatic diseases, a model has
been proposed whereby a mutation in an incident cancer
causes an increase in neo-antigen expression, triggering
an autoimmune anti-tumour cytolytic response. This leads
to successful autoimmune-mediated elimination of the re-
sponsible cancer in some patients [7]. Although the malig-
nancy may be the antigen source initiating the autoimmune
anti-tumour cytolytic response, a cross-reaction against
regenerating cells in other target tissues (e.g. muscle and
skin cells in patients with dermatomyositis) may initiate a
self-propagating “feed-forward” loop of tissue damage and
induced autoimmunity in genetically susceptible individ-
uals. These observations support the “immunosurveillance”
hypothesis; the continual eradication of nascent tumour
cells via immunoediting and triggering of cellular and
humoral immune responses.
In view of the possible association between incident
cancers and induced secondary autoimmunity, we
undertook a pilot study to ascertain whether serotyping
by the gold standard of radiolabelled immunoprecipita-
tion (IP) would uncover evidence of clinically covert
CTD-associated autoantibody generation in patients
with primary lung cancer and without clinically overt
connective tissue disease.
Methods
Patient cohort
Caucasian patients with lung cancer had already been
recruited via the ChemoRes EU Framework 6 integrated
project (https://www.cruk.manchester.ac.uk/Our-Research
/CEP/Areas-of-Interaction-with-Other-Teams), designed
to improve the outcome of cancer chemotherapy. These
patients were recruited into a prospective, single-centre
study being conducted at the Christie Hospital, Manches-
ter, UK. To be eligible for ChemoRes study inclusion,
small cell lung cancer (SCLC) had to be histologically or
cytopathologically confirmed, and disease had to naïve to
chemotherapy and staged and managed using standard
treatment protocols. Non-small cell lung cancer (NSCLC)
had to histologically proven and radiologically confirmed
as stage IIIA, IIIB or IV disease, and also had to be naïve
to chemotherapy [8]. For our pilot serological study we
opportunistically recruited 30 each of these patients with
SCLC and NSCLC from ChemoRes. All patients gave their
written, informed consent to the ethically approved study
protocols. Peripheral blood samples for IP testing were
collected in the 7 days prior to commencing their planned
ChemoRes treatment, and serum was separated according
to standard operating procedures and good clinical labora-
tory practice. Clinical data including age, gender, ethnicity,
diagnosis and smoking status were collected.
Autoantibody testing
Autoantibody testing for myositis and scleroderma spe-
cific and associated autoantibodies: Jo-1, PMScl, snRNP,
Mi-2, Ku, PL12, PL7, EJ, KS, OJ, Zo, Ha, Topo, U3, SRP,
TIF1, SAE, MDA5, Ro60, La, RNA Polymerase I-III,
AMA, Th/To, NXP2, EIF3 and EIF2B, was carried out
by IP using radiolabelled 35S-methionine on patient
serum, as described previously [9]. Serum from patients
positive for known myositis and scleroderma autoanti-
bodies were included as controls. Antibody positivity by
IP was confirmed using the EUROLINE Autoimmune
Inflammatory myopathies (IgG) recombinant line-blot
technology (Euroimmun, Lübeck, Germany).
When patients immunoprecipitated bands at 140 kDa/
155 kDa, their samples were screened also by TIF1γ
ELISA using rTIF1γ (Origene, USA), according to stand-
ard protocols. All samples were tested in duplicate with
a positive cutoff defined as > 3 SD above the mean of 40
healthy controls.
Results
Demographic data for the two patient cohorts are
shown in Table 1. Myositis specific autoantibodies against
glycyl-transfer RNA (tRNA) synthetase (anti-EJ) were iden-
tified by IP in one patient with NSCLC (Additional file 1:
Figure S1). This antibody specificity was also positive by
line-blot testing, with a semi-quantitative value of +++.
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Although TIF1γ autoantibodies have been strongly associ-
ated with malignancy in dermatomyositis, none of the 60
patients with lung cancer tested positive for anti-TIF1,
anti-NXP2 or anti-RNAP III autoantibodies (by either IP or
TIF1γ ELISA), indicating that these autoantibodies are rare
in patients with lung cancer without an autoimmune dis-
ease. No other known myositis or scleroderma autoanti-
bodies were identified.
A total of 55 patients (including the patient with
anti-EJ) had one or more unknown bands on IP, which did
not correspond to any known CTD autoantigen. Although
these were generally moderate or strong bands, indicating
the possible presence of an autoantibody, 10 patients (5
with SCLC and 5 with NSCLC) had only weak bands
thought to represent non-specific binding: the remaining
5 patients were completely negative by IP; all had SCLC.
Anti-glycl-tRNA synthetase (anti-EJ)-positive patient
The anti-EJ-positive patient was female, and aged 67
years. She was a former smoker, starting at age 17 years,
but stopped 2 years prior to her lung cancer diagnosis.
The patient originally presented with right arm and
shoulder discomfort with reduced shoulder movements,
initially diagnosed as arthritis. She had normal exercise
tolerance at presentation. A computerized tomography
(CT) scan revealed a large spiculated mass in the poster-
ior segment of the right upper lobe. Significantly en-
larged lymph nodes were seen in the supraclavicular,
right paratracheal, prevascular, subcarinal and right hilar
regions. The CT scan showed no evidence of interstitial
lung disease. Histological analysis confirmed poorly dif-
ferentiated adenocarcinoma. Immunohistochemical ana-
lysis demonstrated positivity for cytokeratin 7, thyroid
transcription factor-1 and carcinoembryonic antigen
125. Tumour cells were negative for cytokeratin 20,
gross cystic disease fluid protein 15 and oestrogen recep-
tor, in keeping with metastatic adenocarcinoma, primary
non-small cell lung cancer. Somatic mutation in the epi-
dermal growth factor receptor (EGFR) gene or presence
of anaplastic lymphoma receptor tyrosine kinase (ALK)
gene fusion was not present. Following four cycles of
carboplatin and gemcitabine, follow-up CT demon-
strated progressive disease with increase in the size of
the lung mass plus satellite lesions plus a new right
pleural effusion, even though the patient had improved
symptomatically. The patient survived 155 days
(5.1 months) from the date of her consent to participate
in the ChemoRes study.
Discussion
In this pilot study, we used IP to interrogate for the pres-
ence of myositis and scleroderma specific and associated
autoantibodies in individuals with primary lung cancer.
We identified one patient with NSCLC with autoantibodies
against glycyl-tRNA synthetase (anti-EJ), subsequently con-
firmed by line-blot testing. No other CTD autoantibodies
were identified, including antibodies against TIF1γ, NXP2
or RNAP III. We conclude that known myositis and sclero-
derma specific and associated autoantibodies are rare in
patients with lung cancer without a known CTD. These re-
sults are in keeping with those from a recent study that
similarly tested for anti-TIF1γ, anti-NXP2, and anti-RNAP
III autoantibodies in patients with breast cancer without
rheumatic disease [10]. Taken together, these findings sug-
gest that immune-mediated anti-tumor cytolytic responses
in patients with cancer rarely induce paraneoplastic CTDs,
or that patients with cancer without an associated CTD fail
to mount an immune response sufficiently strong to
induce paraneoplastic consequences. Although five pa-
tients in our study were autoantibody negative by IP, the
remaining patients had unidentified bands, potentially indi-
cating the presence of autoantibodies targeting unknown
antigens. This is consistent with the large number of auto-
antibodies that have been reported in cancer, and the role
of immune homeostasis and a humoral immune response
in cancer pathogenesis [6].
To our knowledge, this is the first report of
anti-glycyl-tRNA synthetase autoantibodies in a patient
without a known anti-synthetase syndrome. Anti-EJ
autoantibodies are identified in only ~ 1% of adult
Caucasian patients with IIM [4].
Table 1 Patient demographics
Characteristic SCLC (n = 30) NSCLC (n = 30)
Age at onset, years
Median 68 67
Range 48–82 53–78
Sex
Female 18 15
Male 12 15
Diagnosis
Limited 13
Extensive 17
Adenocarcinoma 12
Squamous cell carcinoma 8
Other 2
Not documented 8
Smoking status
Current smoker 14 6
Former smoker 14 14
Never-smoker 0 3
Not documented 2 7
SCLC small cell lung cancer, NSCLC non-small cell lung cancer
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A limitation of this pilot study is the lack of follow-up
clinical data relating to complete ascertainment of CTD
or anti-synthetase syndrome development; the patient
seropositive for anti-EJ lived only 155 days following
consent to participate in the ChemoRes study. Patients
were recruited as part of a project to improve the out-
come of cancer chemotherapy, and so were referred to
oncologists rather than rheumatologists. Subtle CTD
clinical features therefore could have been overlooked.
Alternatively, anti-EJ autoantibodies may have been de-
tectable in this patient’s serum prior to the development
of overt CTD clinical signs, as reported in patients sero-
positive for rheumatoid factor before they develop overt
rheumatoid arthritis. The median age of lung cancer on-
set in this pilot study was 68 years and 67 years in SCLC
and NSCLC, respectively. In a large international study
of IIM, the mean age of IIM onset was ~ 50 years, and
was 57 years in those with malignancy, with a median
interval between IIM onset and associated cancer diag-
noses of only 1 month [11], suggesting possible selection
against patients with cancer-associated myositis in the
present study.
There is currently an unmet clinical need for biomarkers
to facilitate early detection of lung and other cancers.
Recent progress in the treatment of lung cancer with im-
mune therapies reinforces the need to better understand
host immune responses in the context of lung cancer.
Although the presence of a cancer-associated autoanti-
body or paraneoplastic syndrome could potentially signify
a tumuor more likely to respond to an immunomodula-
tory approach, the low prevalence of CTD autoantibodies
identified in this series counters their potential utility in
an unselected population. Notably, however, the relatively
small number of patients with cancer included in this
study limits our ability to detect rare or low-frequency
autoantibodies; utility in screening should be addressed
using larger cohorts with longitudinal follow-up data.
Conclusions
In patients with lung cancer without an associated CTD,
myositis and scleroderma specific and associated autoanti-
bodies, including anti-TIF1, anti-NXP2 and anti-RNAP III,
are rare. We identified one patient with NSCLC with
anti-EJ autoantibodies, the first time that this anti-synthe-
tase autoantibody has been reported in a patient without
anti-synthetase syndrome clinical features.
Additional file
Additional file 1: Figure S1. Radio-immunoprecipitation of NSCLC
samples and positive controls. A Autoradiograph of a 10% SDS-PAGE,
loaded with immunoprecipitates using either serum containing known auto-
antibodies (Lane 1: Healthy Control/Normal Serum (NS), Lane 2: anti-Jo-1 and
anti-U1RNP/Sm, Lane 3: anti-PMScl, anti-Ro60 and anti-La, Lane 4:
anti-Mitrochondrial autoantibodies (AMAs), Lane 5; anti-Ku and anti-
Mi-2), or NSCLC samples screened as part of this study (lanes 6–14).
The sample loaded into lane 11 (NSCLC269, marker with *) contains
anti-EJ autoantibodies. B Autoradiograph of a 10% SDS-PAGE, loaded
with immunoprecipitates using serum known to contain anti-EJ auto-
antibodies (lanes 1–4) or NSCLC269 identified as containing anti-EJ.
(PPTX 309 kb)
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